- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
CAR T-Cell Therapy | Clinical
Behind the FDA Approval: Liso-Cel for R/R Large B-Cell Lymphoma
June 30, 2022
In an interview with Targeted Oncology, Manali Kamdar, discussed the recent FDA approval of lisocabtagene maraleucel for the treatment of patients with relapsed or refractory large B-cell lymphoma, and how community oncologists should approach patient referrals and post-treatment care.
FDA Approves Liso-Cel for Second-Line Treatment of R/R LBCL
June 25, 2022
The FDA has granted approval lisocabtagene maraleucel for the treatment of adult patients with large B-cell lymphoma, with specific indications for patients with relapsed or refractory disease.
Second CAR T Infusion Could Lead to New Response in B-ALL
June 18, 2022
Several treatment options are being explored for patients who have residual disease or who relapse after CAR T-cell therapy, including a possible second infusion with the same CAR T-cell product.
Investigation of Novel CAR T Product, MB-106, in Various R/R B-Cell Malignancies
June 16, 2022
In an interview with Targeted Oncology, Mazyar Shadman, MD, MPH, discussed his research of MB-106 as treatment for patients with relapsed or refractory B-non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Understanding CAR T-Cell Therapy Utilization Patterns in the Community Oncology Setting
June 08, 2022
In an interview with Targeted Oncology™, Bruce Feinberg, DO, discussed the use of CAR T-cell therapy in the community oncology setting, the challenges oncologist face, and the next wave of innovation to improve CAR T-cell administration for patients.
Durable Response Elicited With CLDN18.2-Directed CAR T-cell Therapy in Gastrointestinal Cancers
June 05, 2022
Treatment with a Claudin18.2–specific chimeric antigen receptor T-cell therapy has demonstrated either a response or stable disease in patients with heavily pretreated advanced gastric and pancreatic adenocarcinoma.
Community Providers Face Hurdles With CAR T-Cell Therapy Referrals and In-Office Infusion
June 03, 2022
Few community practices are performing in-office infusions on CAR T-cell therapy, but due to interest from 20% of them, experts recommend stakeholder alignment to address the concerns of the oncology population.
Blocking TIGIT May Help With Dipping Remission Rates in NHL After CAR T-Cell Therapy
May 19, 2022
In preclinical study, researchers have identifies anti-TIGIT therapy as a potentially effective strategy for improving remission rates in patients with non-Hodgkin lymphoma after chimeric antigen receptor T-cell therapy.
High-Dose Anakinra Shows Promise in Treating CRS/ICANS Post CAR T-Cell Therapy
May 18, 2022
In an interview with Targeted Oncology, Nicolas Gazeau, further discusses his analysis of anakinra when administered at 2 different dose regimens for patients with refractory CRS/ICANS after CAR T-cell therapy.
First Patient Dosed in IMAGINE Trial Evaluating MT-101 in Patients With PTCL
May 13, 2022
Investigators of the phase 1/2 IMAGINE study, evaluating MT-101 in patients with refractory or relapsed peripheral T-cell lymphoma, have dosed its first patient.